Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Authors:
Janelle M Hoskins
Janelle M Hoskins
University of North Carolina
United States
Eugenio Marcuello
Eugenio Marcuello
Hospital de la Santa Creu i Sant Pau
Albert Altes
Albert Altes
Universitat Internacional de Catalunya
Sharon Marsh
Sharon Marsh
Washington University School of Medicine
United States
Taylor Maxwell
Taylor Maxwell
Washington University School of Medicine
United States
Robert Culverhouse
Robert Culverhouse
Washington University School of Medicine
United States

Clin Cancer Res 2008 Mar;14(6):1788-96

Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Purpose: Irinotecan is an important drug for the treatment of solid tumors. Although genes involved in irinotecan pharmacokinetics have been shown to influence toxicity, there are no data on pharmacodynamic genes. CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan. Polymorphisms in the drug target of camptothecins, topoisomerase I (TOP1), and downstream effectors may influence patient outcomes to irinotecan therapy. We undertook a retrospective candidate gene haplotype association study to investigate this hypothesis.

Experimental Design: Haplotype compositions of six candidate genes were constructed in European (n = 93), East Asian (n = 94), and West African (n = 95) populations. Haplotype-tagging single nucleotide polymorphisms (htSNP) were selected based on genealogic relationships between haplotypes. DNA samples from 107 European, advanced colorectal cancer patients treated with irinotecan-based regimens were genotyped for htSNPs as well as three coding region SNPs. Associations between genetic variants and toxicity (grade 3/4 diarrhea and neutropenia) or efficacy (objective response) were assessed.

Results: TOP1 and TDP1 htSNPs were related to grade 3/4 neutropenia (P = 0.04) and response (P = 0.04), respectively. Patients homozygous for an XRCC1 haplotype (GGCC-G) were more likely to show an objective response to therapy than other patients (83% versus 30%; P = 0.02). This effect was also seen in a multivariate analysis (odds ratio, 11.9; P = 0.04). No genetic variants were associated with diarrhea.

Conclusions: This is the first comprehensive pharmacogenetic investigation of irinotecan pharmacodynamic factors, and our findings suggest that genetic variation in the pharmacodynamic genes may influence the efficacy of irinotecan-containing therapies in advanced colorectal cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1472DOI Listing
March 2008
7 Reads

Publication Analysis

Top Keywords

pharmacodynamic genes
12
objective response
8
grade 3/4
8
colorectal cancer
8
advanced colorectal
8
genetic variants
8
cancer patients
8
irinotecan
6
genes
5
influence
5
polymorphisms htsnp
4
htsnp selected
4
002 multivariate
4
single nucleotide
4
multivariate analysis
4
haplotype-tagging single
4
30% 002
4
nucleotide polymorphisms
4
based genealogic
4
haplotypes dna
4

Altmetric Statistics

Similar Publications

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

J Pharmacol Exp Ther 2013 Apr 5;345(1):95-101. Epub 2013 Feb 5.

Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada.

Despite the importance of UDP-glucuronosyltransferase (UGT) 1A1*28 in irinotecan pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited. We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens. The relationships between UGT1A candidate markers across the gene (n = 21) and toxicity were prospectively evaluated in 167 patients. Read More

View Article
April 2013

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Pharmacogenomics 2009 Jul;10(7):1139-46

UNC Institute for Pharmacogenomics & Individualized Therapy, University of North Carolina, Genetic Medicine Building, Chapel Hill, NC 27599-7360, USA.

Aims: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan.

Materials & Methods: DNA was isolated from 85 advanced cancer patients treated with 300 or 350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1, TDP1 and XRCC1. Read More

View Article
July 2009

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Pharmacogenet Genomics 2007 Jul;17(7):497-504

Division of Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Objectives: SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on UGT1A haplotypes covering all these isoforms is important for the individualized therapy of irinotecan. Associations between UGT1A haplotypes and pharmacokinetics/pharmacodynamics of irinotecan were investigated to identify pharmacogenetic markers. Read More

View Article
July 2007

Pharmacogenetics of irinotecan disposition and toxicity: a review.

Curr Clin Pharmacol 2010 Aug;5(3):209-17

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospotal, Memphis, TN 38105-3678, USA.

Irinotecan (CPT-11) is a widely used anticancer drug, especially for the treatment of colorectal cancer. Irinotecan is considered an inactive prodrug that requires activation to the active metabolite SN-38. Patients treated with irinotecan occasionally experience severe neutropenia and delayed diarrhea, and the occurrence of these adverse reactions is unpredictable and still largely unexplained. Read More

View Article
August 2010